![Lazard advised on healthcare firm Gilead’s $21bn acquisition of cancer drug-maker Immunomedics](https://s.wsj.net/public/resources/images/FN-AM598_FN_Laz_M_20210205091657.jpg)
Lazard chief executive, Ken Jacobs, sees "pent up demand" for M&A fuelling results in 2021 after the independent investment bank ended the year with its a record quarter for its advisory business.
Jacobs told Financial News that increased confidence following the rollout of the Covid-19 vaccine, as well as expansionary technology-enabled companies was fuelling more dealmaking.